May 2015

CoLucid Pharmaceuticals Raises $55M in IPO

In May 2015, CoLucid Pharmaceuticals (Nasdaq: CLCD) completed a $55 million initial public offering. Our firm represented Boston-based CoLucid, completing the IPO in just three months.

CoLucid is a Phase 3 clinical-stage biopharmaceutical company that is developing an innovative and proprietary small molecule for the acute treatment of migraine headaches.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.